BioSyent (TSXV: RX) has entered into a Share Purchase Agreement to acquire closely held Oral Science, a Canadian distributor of specialized healthcare products for dental hygiene and oral health based in Brossard, Quebec.
The agreement includes BioSyent’s acquisition of Oral Science in an arm’s-length transaction for $25.5 million, consisting of C$22.5 million in cash and 234,192 BioSyent common shares valued at C$12.81 per share. Some of the shares will be subject to a two-year escrow or lock-up, with 25% of the locked-up shares released every six months. The purchase price includes a C$6.3 million net working capital requirement at closing.
Oral Science may also receive a contingent cash earn-out in 2027 based on its performance in 2025 and 2026, along with royalty payments through 2033 tied to sales of one product, capped at C$6.0 million.
The transaction is expected to close before the end of February 2026, subject to customary closing conditions and regulatory approvals.
